Previous 10 | Next 10 |
2023-03-04 13:45:00 ET A record $138B was invested by the 15 largest pharmaceutical companies in 2022, a staggering 43% increase since 2017, according to an IQVIA report. That $138B accounted for ~19% of these companies' overall sales. IQVIA also found that although biopharma in...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Cassava Sciences press release ( NASDAQ: SAVA ): Q4 GAAP EPS of -$0.47 beats by $0.11 . At December 31, 2022, cash and cash equivalents were $201 million, compared to $233.4 million at December 31, 2021, with no debt. Year-end cash balance included net proceeds of $47.3 millio...
In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease. In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study. In Q4 2023, We Expect to Complete Patient Enrollment for our Phase 3 Studies of Simufil...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips One in every nine seniors is living with Alzheimer’s disease , and the race to cure it is worth big money. While the FDA has approved some Alzheimer’s disease drugs, these can only slow the progression, not halt ...
Summary Cassava's pivotal Phase 3 studies roll on and are expected to be fully enrolled by the end of 2023 - an admirable achievement. Meanwhile, the latest Phase 2 Open Label knocked the share price. The data releases from these studies have gotten progressively less encouraging - ...
Casava Sciences ( NASDAQ: SAVA ) said it plans to finish enrollment in two phase 3 studies of Alzheimer's drug simufilam by the end of 2023. So far, 953 patients have been enrolled in both studies. The goal is to enroll 1750 patients total. Currently, both studies have passed th...
953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023 AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cass...
Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...
On any list of biotech plays that might multiply in value in a relatively short period, Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. It's exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease, though it...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...